Risk of ventricular dysrhythmias during 1-hour infusions of amphotericin B in patients with preserved renal function

Antimicrob Agents Chemother. 1992 Nov;36(11):2542-3. doi: 10.1128/AAC.36.11.2542.

Abstract

In order to assess the safety of 1-h infusions of amphotericin B (AMB), we prospectively monitored 213 1-h infusions of AMB (dose range, 0.27 to 0.89 mg/kg of body weight) in 27 patients with creatinine clearances of > 25 ml/min. Holter monitor tracings during 1-h infusions were compared with those during a 4-h baseline period of monitoring. There were no ventricular dysrhythmias during 1-h infusions of AMB that were not present during baseline monitoring. Nausea and/or rigors were noted for 32 (15%) infusions in six (22%) patients. No patient exhibited a temperature rise of > 1 degree C. We conclude that, in doses of up to 0.9 mg/kg, AMB does not appear to induce asymptomatic ventricular dysrhythmias when administered over 1 h to patients with creatinine clearances of > 25 ml/min.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Amphotericin B / administration & dosage
  • Amphotericin B / adverse effects*
  • Arrhythmias, Cardiac / chemically induced*
  • Drug Administration Schedule
  • Electrocardiography, Ambulatory
  • Female
  • Heart Ventricles / drug effects
  • Humans
  • Infusions, Intravenous
  • Kidney / physiology*
  • Male
  • Middle Aged
  • Prospective Studies
  • Ventricular Fibrillation / chemically induced
  • Ventricular Function / drug effects*

Substances

  • Amphotericin B